A detailed history of Charles Schwab Investment Management Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 484,797 shares of REPL stock, worth $6.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
484,797
Previous 432,299 12.14%
Holding current value
$6.06 Million
Previous $3.89 Million 36.58%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$8.09 - $11.23 $424,708 - $589,552
52,498 Added 12.14%
484,797 $5.31 Million
Q2 2024

Aug 12, 2024

BUY
$5.01 - $9.46 $68,311 - $128,987
13,635 Added 3.26%
432,299 $3.89 Million
Q1 2024

May 08, 2024

BUY
$6.87 - $9.31 $114,880 - $155,681
16,722 Added 4.16%
418,664 $3.42 Million
Q4 2023

Feb 06, 2024

BUY
$6.75 - $16.18 $159,516 - $382,365
23,632 Added 6.25%
401,942 $3.39 Million
Q3 2023

Nov 08, 2023

BUY
$15.96 - $22.18 $1.49 Million - $2.07 Million
93,364 Added 32.77%
378,310 $6.47 Million
Q2 2023

Aug 09, 2023

SELL
$15.65 - $24.1 $183,214 - $282,138
-11,707 Reduced 3.95%
284,946 $6.62 Million
Q1 2023

May 11, 2023

BUY
$17.48 - $29.09 $648,088 - $1.08 Million
37,076 Added 14.28%
296,653 $5.24 Million
Q4 2022

Feb 13, 2023

BUY
$17.09 - $27.91 $125,389 - $204,775
7,337 Added 2.91%
259,577 $7.06 Million
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $659,989 - $894,793
42,307 Added 20.15%
252,240 $4.36 Million
Q2 2022

Aug 15, 2022

SELL
$13.32 - $19.98 $78,774 - $118,161
-5,914 Reduced 2.74%
209,933 $3.67 Million
Q1 2022

May 13, 2022

BUY
$15.24 - $29.75 $105,963 - $206,851
6,953 Added 3.33%
215,847 $3.67 Million
Q4 2021

Feb 11, 2022

BUY
$25.43 - $34.25 $92,514 - $124,601
3,638 Added 1.77%
208,894 $5.66 Million
Q3 2021

Nov 16, 2021

BUY
$28.98 - $39.54 $694,418 - $947,457
23,962 Added 13.22%
205,256 $6.08 Million
Q2 2021

Aug 16, 2021

BUY
$28.5 - $39.37 $215,887 - $298,227
7,575 Added 4.36%
181,294 $6.97 Million
Q1 2021

May 17, 2021

BUY
$30.22 - $45.57 $262,611 - $396,003
8,690 Added 5.27%
173,719 $5.3 Million
Q4 2020

Feb 16, 2021

BUY
$23.5 - $52.65 $687,892 - $1.54 Million
29,272 Added 21.56%
165,029 $6.3 Million
Q3 2020

Nov 13, 2020

BUY
$18.85 - $27.0 $1.79 Million - $2.56 Million
94,999 Added 233.08%
135,757 $3.13 Million
Q2 2020

Aug 14, 2020

BUY
$9.76 - $25.95 $80,656 - $214,450
8,264 Added 25.43%
40,758 $1.01 Million
Q1 2020

May 15, 2020

BUY
$8.9 - $19.08 $11,427 - $24,498
1,284 Added 4.11%
32,494 $324,000
Q4 2019

Feb 07, 2020

BUY
$11.61 - $17.21 $41,192 - $61,061
3,548 Added 12.83%
31,210 $448,000
Q1 2019

May 14, 2019

BUY
$10.26 - $16.24 $138,530 - $219,272
13,502 Added 95.35%
27,662 $422,000
Q3 2018

Nov 13, 2018

BUY
$14.99 - $22.14 $212,258 - $313,502
14,160 New
14,160 $228,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.